Apollomics to Present at the Canaccord Genuity 44th Annual Growth Conference
Apollomics Inc. - Class A Ordinary Shares (APLM)
Company Research
Source: GlobeNewswire
FOSTER CITY, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced the Company management will be presenting at the Canaccord Genuity 44th Annual Growth Conference taking place on August 13-15, 2024 in Boston, MA. Canaccord Genuity 44th Annual Growth Conference Format: Company presentationPresentation Date & Time: Tuesday, August 14, 2024 at 9:30 am ETLocation: InterContinental Boston HotelPresenter: Matthew Plunkett, PhD, Chief Financial Officer of ApollomicsWebcast: Click here Management will be available for one-on-one meetings during the conference. Interested investors should contact their Canaccord Genuity representative to request meetings. A link to access company presentation, when available, will be posted to Company website on the Events page under
Show less
Read more
Impact Snapshot
Event Time:
APLM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
APLM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
APLM alerts
High impacting Apollomics Inc. - Class A Ordinary Shares news events
Weekly update
A roundup of the hottest topics
APLM
News
- Apollomics Presents Vebreltinib Data in Patients with Non-Small Cell Lung Cancer with METex14 Skipping Mutations at European Society for Medical Oncology (ESMO) Congress 2024GlobeNewswire
- Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceGlobeNewswire
- Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical ProgressGlobeNewswire
- Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA TrialGlobeNewswire
- Apollomics Granted 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price RequirementGlobeNewswire
APLM
Sec Filings
- 8/15/24 - Form SC
- 8/14/24 - Form 6-K
- 8/1/24 - Form 6-K
- APLM's page on the SEC website